Studies carried out with BC patients had already reported a lower FRAP level in disease samples when compared with healthy ones [34,64], but there is no precedent showing HER2+ BC cases to be distinguished from HER2− BC cases by their serum’s antioxidant capacity (reducing power). The gene discussed is ERBB2; the disease is breast cancer.